Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Vitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin,
affecting 0.5–2% of the population worldwide. It can have a significant impact on patients' …

Vitiligo is an autoimmune disease of the skin that results in disfiguring white spots. There are
no US Food and Drug Administration–approved treatments for vitiligo, and most off-label …

Importance Narrowband UV-B (NB–UV-B) phototherapy is used extensively to treat vitiligo.
Afamelanotide, an analogue of α–melanocyte-stimulating hormone, is known to induce …

Importance Topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus,
have been widely used for the treatment of vitiligo; however, the efficacy of TCI monotherapy …

Vitiligo is a chronic, acquired depigmenting condition of the skin, and sometimes of the
mucosa, that results in the selective loss of melanocytes. 1 Vitiligo has been reported since …

Vitiligo is a disease characterized by disappearance of melanocytes from the skin. It can
negatively influence the physical appearance of affected individuals, and may profoundly …

Vitiligo is an acquired pigmentry disorder of the skin and mucous membranes which
manifests as white macules and patches due to selective loss of melanocytes. Etiological …

Clinical Question Which interventions are associated with highest efficacy and fewest
adverse events for treating vitiligo? Bottom Line Combination therapies, particularly those …

The present study aimed to investigate the role of janus kinase (JAK) 1/STAT1 in interferon
(IFN)‑γ‑induced apoptosis in human melanocytes. Following IFN‑γ treatment, the viability of …